Skip to main content
Realcan Pharmaceutical Group Co.,Ltd. logo

Realcan Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 002589 ISIN · CNE1000013X5 LEI · 300300YI5IV3FBRRSJ48 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,678 across all filing types
Latest filing 2020-04-28 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 002589

About Realcan Pharmaceutical Group Co.,Ltd.

https://www.realcan.cn

Realcan Pharmaceutical Group Co., Ltd. specializes in the distribution of pharmaceutical products, medical devices, and healthcare consumables. The company operates an extensive supply chain network, providing integrated logistics and distribution services primarily to medical institutions and healthcare providers. Its core operations include the procurement, storage, and delivery of a wide range of medical supplies, supported by advanced information management systems and cold-chain logistics capabilities. Realcan also offers value-added services such as hospital supply chain optimization, third-party logistics, and financial solutions tailored to the healthcare industry. By focusing on a direct-to-hospital distribution model, the company aims to enhance the efficiency of medical supply procurement and ensure the timely delivery of critical healthcare products.

Recent filings

Filing Released Lang Actions
内部控制鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as an "内部控制鉴证报告" which translates to "Internal Control Assurance Report". It is issued by a certified public accounting firm and includes an auditor's opinion on the effectiveness of the company's internal control over financial reporting as of December 31, 2019. The document references compliance with regulatory standards issued by the Ministry of Finance, CSRC, Audit Office, and other regulatory bodies. It contains detailed descriptions of the company's internal control systems, management responsibilities, audit procedures, and conclusions on internal control effectiveness. The document length is substantial (over 13,000 characters) and contains the actual audit opinion and detailed internal control evaluation, not just an announcement or certification. This matches the definition of an Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles related to internal control effectiveness. It is not an Annual Report (10-K) because it does not contain full financial statements or comprehensive company activity reports. It is not a Regulatory Filing (RNS) because it contains substantive audit content rather than just certifications or announcements. Therefore, the correct classification is AR with high confidence. FY 2019
2020-04-28 Chinese
2020年第一季度报告正文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2020 年第一季度报告正文" which translates to "2020 First Quarter Report Main Text." It contains detailed financial data including income, profit, cash flow, assets, liabilities, and shareholder information for the first quarter of 2020. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year indicates this is an Interim / Quarterly Report. The document length is 7156 characters, which is sufficient to contain substantive financial data, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2020
2020-04-28 Chinese
关于公司2019年度控股股东及其他关联方资金占用情况的专项说明
Audit Report / Information Classification · 95% confidence The document is titled as a "专项说明" (special explanation) regarding the 2019 annual related party and controlling shareholder fund occupation situation of 瑞康医药集团股份有限公司. It includes an auditor's statement from a CPA firm, referencing the 2019 audited financial statements and confirming consistency with the audited financial data. The document is a specialized audit report focusing on related party transactions and fund occupation, not the full annual report or financial statements themselves. It is a standalone audit-related report issued by the auditor, with detailed financial data on related party fund occupation. This fits the definition of an Audit Report / Information (AR) rather than a full Annual Report (10-K) or other categories. The document length (15,000 characters) and content confirm it is a full report, not just an announcement or certification. Therefore, the correct classification is AR with high confidence. FY 2019
2020-04-28 Chinese
独立董事2019年度述职报告（武滨）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director 2019 Annual Work Report" for Rui Kang Pharmaceutical Group Co., Ltd. It is a detailed narrative by an independent director summarizing their duties, attendance at board meetings, opinions expressed, investigations conducted, committee participation, investor protection efforts, training, and other related activities during the 2019 fiscal year. The content focuses on the director's role and responsibilities rather than financial results or audit opinions. It is not a full annual report (10-K), audit report (AR), or management discussion and analysis (MDA). It is also not a regulatory filing or announcement but a formal report by a board member on their activities. This fits best under Board/Management Information (MANG), which covers announcements or reports related to board members and senior management. The document length is 2420 characters, which is consistent with a detailed director's report rather than a brief announcement or a full financial report.
2020-04-28 Chinese
内部控制规则落实自查表
Regulatory Filings Classification · 95% confidence The document is titled as an "内部控制规则落实自查表" which translates to "Internal Control Rules Implementation Self-Inspection Form" for 瑞康医药集团股份有限公司 (Ruikang Pharmaceutical Group Co., Ltd.). It contains detailed internal control checklists related to internal audit operations, information disclosure controls, insider trading controls, fundraising controls, related party transactions, external guarantees, major investments, and other important matters. The document is a self-assessment or compliance checklist rather than a financial report or announcement. It does not contain financial statements, earnings data, or regulatory filings such as audit reports or annual reports. It is a detailed internal control compliance document, which fits best under Regulatory Filings (RNS) as it is a compliance-related disclosure that does not fit other specific categories.
2020-04-28 Chinese
2019年年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled '审计报告' which translates to 'Audit Report'. It includes detailed financial data such as assets, liabilities, equity, and notes, and is signed by certified public accountants (CPAs). The presence of CPA signatures, detailed financial statements, and the report number indicates this is a standalone audit report rather than a full annual report or other filing. The document length is substantial (15,000 characters), containing actual financial data and analysis, not just an announcement or certification. Therefore, it fits the category of Audit Report / Information (AR). FY 2019
2020-04-28 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.